Ustekinumab biosimilar - Dong-A ST

Drug Profile

Ustekinumab biosimilar - Dong-A ST

Alternative Names: DA 3115

Latest Information Update: 27 Jun 2016

Price : $50

At a glance

  • Originator Dong-A ST
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 12 subunit p40 inhibitors; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Psoriasis

Highest Development Phases

  • Research Psoriasis

Most Recent Events

  • 27 Jun 2016 Early research in Psoriasis in South Korea (SC) before June 2016
  • 27 Jun 2016 Ustekinumab biosimilar - Dong-A ST is available for licensing (excluding Japan) as of 27 Jun 2016. http://www.donga-pharm.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top